exaggerated or dysregulated neurodevelopment (Lieberman, 1999; Lieberman et al., 2005; Woods, 1998). These structural differences are extremely dynamic in the first year after psychosis onset; this serves as a caveat to researchers seeking an MRI-based biological marker for genetic or diagnostic studies of schizophrenia, as the deficit level in the illness can vary substantially over time and with treatment. Most studies suggest that the observed changes in disease may represent an abnormal exaggeration of the normal developmental trajectory.
